Switching anti-platelet tablets after a heart stent
Part of Heart & circulation clinical trials.
This trial studies whether changing the timing and type of blood-thinner tablets after a heart stent is as safe and effective as continuing the same plan. It may help some people by simplifying treatment while preventing dangerous clotting after a coronary procedure.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old
- You were diagnosed with an acute coronary syndrome when you were admitted
- You took ticagrelor for at least 30 days after successful PCI (stent placement) using a modern drug-eluting stent
- You can agree to the study visits, follow-up schedule, and sign consent
- You can tolerate a 12-month dual blood-thinner plan with ticagrelor plus aspirin (as required in the study)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether taking a single blood-thinning medication (instead of two) after heart stent placement is safe and effective over the long term. If you've recovered well from a stent procedure, this trial may help determine the safest way to prevent future heart problems.
This study compares ticagrelor taken at a lower dose versus regular aspirin to help prevent future heart attacks in people who recently had a stent placed after acute coronary syndrome. You may qualify if you’re considered “high risk” for new blockages or clots and can take dual anti-platelet therapy for 12 months.
This trial tests an algorithm (computer-guided plan) to choose the best “dual antiplatelet therapy” (two blood-thinning medicines) after a coronary stent. It aims to improve outcomes after the procedure while reducing avoidable problems from the medicines.
This study tests whether taking dabigatran (a blood thinner) combined with ticagrelor (a blood clot preventer) is safe and effective for patients with irregular heart rhythm (atrial fibrillation) who recently had a heart attack and received a stent. The goal is to prevent future blood clots while minimizing bleeding risks.
This trial tests if people who have been on two blood thinners (aspirin plus prasugrel or ticagrelor) for at least 90 days after getting a heart stent can safely switch to just one of those blood thinners. It aims to see if taking only one pill is as safe and effective as taking two.
This study compares two ways to manage blood thinners after a stent. It tests whether switching from stronger drugs (prasugrel or ticagrelor) to clopidogrel is safe and effective for long-term heart protection.
Hear when a new Acute Coronary Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.